Asparaginase Erwinia chrysanthemi (Erwinaze)
FDA approved 11/18/2011
General information
Class/mechanism: Depletes plasma asparagine by catalyzing the deamidation of asparagine to
aspartic acid and ammonia, selectively killing leukemic cells which are unable to synthesize asparagine due to a lack of asparagine synthetase.[1][2]
Route: IM
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Asparaginase patient drug information (Chemocare) -- note: this is for Asparaginase (Elspar), not Erwinaze[3]
- Asparaginase Erwinia chrysanthemi (Erwinaze) patient drug information (UpToDate)[4]
References
- ↑ 1.0 1.1 Asparaginase Erwinia chrysanthemi (Erwinaze) package insert
- ↑ Asparaginase Erwinia chrysanthemi (Erwinaze) package insert (locally hosted backup)
- ↑ Asparaginase Erwinia chrysanthemi (Erwinaze) patient drug information (Chemocare)
- ↑ Asparaginase Erwinia chrysanthemi (Erwinaze) patient drug information (UpToDate)